Styx, a pioneering biotech startup, is committed to transforming immunotherapy and cancer vaccine development by emphasizing enhanced immune memory for cancer treatment and prevention, particularly for challenging cancer types. The company's pipeline includes innovative CAR-T cell therapy product candidates targeting both solid and liquid tumors, as well as vaccine candidates addressing patient populations with high unmet medical need. With a mission to develop safer, more effective, and long-lasting immunotherapies and vaccines, Styx Biotechnologies is dedicated to improving global health outcomes and fostering a healthier future for all.
Company Details
- Employees
- 2
- Founded
- -
- Address
- San Diego, California, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- San Diego, California
Styx Biotechnologies Questions
Styx Biotechnologies's LinkedIn profile is https://www.linkedin.com/company/styx-biotechnologies
Styx Biotechnologies has
2 employees.
View email and phone details for 2
employees at Styx Biotechnologies.
Styx Biotechnologies's industry is
Biotechnology Research
Styx Biotechnologies's top competitors are
Palm Therapeutics,
Aivo Biosciences,
Mivax Therapeutics,
Myogene Bio,
Abintus Bio, Inc.,
F5 Therapeutics Incorporated,
Origami Therapeutics, Inc.,
Aivocode,
Navega Therapeutics,
Trestle Biotherapeutics.
Styx Biotechnologies's categories are Biotechnology Research
Styx Biotechnologies's founding year is 2021
